SRRK250117C20000
- 14.90
- 0.000.00%
Scholar Rock Newsroom
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Scholar Rock Plans Apitegromab Commercialization, Expanded Use in 2025
Express News | Scholar Rock Holding Corp - Initiating Phase 2 Opal Trial in Sma Patients Under Two Years Old in Mid- 2025
Express News | Scholar Rock Holding Corp -Filing of Ind Application for Srk-439 on Track for 3Q 2025
Express News | Scholar Rock Highlights 2025 Strategic Priorities
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
10 Health Care Stocks With Whale Alerts In Today's Session
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Scholar Rock(SRRK.US) 10% Shareholder Sells US$15.76 Million in Common Stock
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $45
Scholar Rock Price Target Raised to $45 From $36 at Truist
H.C. Wainwright Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $50
Promising Market Dynamics and Growth Potential for Scholar Rock's Apitegromab Boost Buy Rating
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $50
Express News | Scholar Rock Holding Corp : H.c. Wainwright Raises Target Price to $50 From $40
U.S. Small Caps Rise; Scholar Rock Holding Climbs Highest